Placing a Value on New Technologies

Heidenreich, Paul A.

doi:10.1161/circulationaha.113.003196

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

2018

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there remains considerable reticence around the cost of such therapies. 12 Together these data support that it would be unlikely that in 2013 that large pharmaceutical companies would be pursuing research to discover a new compound like dobutamine.…”

mentioning

confidence: 87%

See 1 more Smart Citation

Can We Do Better Than Dobutamine?

McNally

2013

Circulation Research

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 87%

“…Since 1995, there has been no significant decline in heart failure, reflecting the absence of new medical developments for its treatment. 12 …”

mentioning

confidence: 99%

Can We Do Better Than Dobutamine?

McNally

2013

Circulation Research

View full text Add to dashboard Cite

show abstract

“…However, the most common etiologies of HF are the coronary artery diseases and myocardial infarction (MI) (1). HF affects more than 5 million adult Americans and this number is expected to increase to be > 8 million in 2030 (2,3). Fifty percent of patients with HF are readmitted to the hospital within 6 months of discharge (4) and half of them die within 5 years of diagnosis (2).…”

Section: Introductionmentioning

confidence: 99%

Protein Kinase A as a Promising Target for Heart Failure Drug Development

Saad¹,

Elnakish²,

Ahmed

et al. 2018

Archives of Medical Research

View full text Add to dashboard Cite

Heart failure (HF) is a clinical syndrome characterized by impaired ability of the heart to fill or eject blood. HF is rather prevalent and it represents the foremost reason of hospitalization in the United States. The costs linked to HF overrun those of all other causes of disabilities, and death in the United States and all over the developed as well as the developing countries which amplify the supreme significance of its prevention. Protein kinase (PK) A plays multiple roles in heart functions including, contraction, metabolism, ion fluxes, and gene transcription. Altered PKA activity is likely to cause the progression to cardiomyopathy and HF. Thus, this review is intended to focus on the roles of PKA and PKA-mediated signal transduction in the healthy heart as well as during the development of HF. Furthermore, the impact of cardiac PKA inhibition/activation will be highlighted to identify PKA as a potential target for the HF drug development.

show abstract

MI to Cool?

Lundbye

Fernández

2015

Therapeutic Hypothermia and Temperature Management

View full text Add to dashboard Cite

Placing a Value on New Technologies

Cited by 3 publications

References 19 publications

Can We Do Better Than Dobutamine?

Can We Do Better Than Dobutamine?

Protein Kinase A as a Promising Target for Heart Failure Drug Development

MI to Cool?

Contact Info

Product

Resources

About